12/4
02:40 pm
bmrn
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory [Yahoo! Finance]
12/3
08:42 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.
11/26
07:52 pm
bmrn
BioMarin Pharmaceutical (BMRN): Evaluating Valuation After Raised Guidance on Revenue Strength [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical (BMRN): Evaluating Valuation After Raised Guidance on Revenue Strength [Yahoo! Finance]
11/25
01:48 pm
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
05:23 am
bmrn
2 Reasons to Like BMRN and 1 to Stay Skeptical [Yahoo! Finance]
Low
Report
2 Reasons to Like BMRN and 1 to Stay Skeptical [Yahoo! Finance]
11/14
02:40 am
bmrn
Examining BioMarin Stock After Pipeline Advances and Recent Price Rebound in 2025 [Yahoo! Finance]
Low
Report
Examining BioMarin Stock After Pipeline Advances and Recent Price Rebound in 2025 [Yahoo! Finance]
11/11
09:00 am
bmrn
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
Medium
Report
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
11/11
04:29 am
bmrn
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth [Yahoo! Finance]
Medium
Report
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth [Yahoo! Finance]
11/6
08:10 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "hold" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "hold" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
11/5
09:09 pm
bmrn
J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) [Yahoo! Finance]
Medium
Report
J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) [Yahoo! Finance]
11/4
10:13 am
bmrn
BioMarin (BMRN): Valuation Insights After Revenue Upside and PALYNZIQ Expansion News [Yahoo! Finance]
Low
Report
BioMarin (BMRN): Valuation Insights After Revenue Upside and PALYNZIQ Expansion News [Yahoo! Finance]
11/3
08:44 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $88.00 price target on by analysts at Tudor Pickering.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $88.00 price target on by analysts at Tudor Pickering.
11/3
08:03 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Sanford C. Bernstein from $95.00 to $88.00. They now have an "outperform" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Sanford C. Bernstein from $95.00 to $88.00. They now have an "outperform" rating on the stock.
11/1
01:04 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) was downgraded by analysts at
Wall
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) was downgraded by analysts at
Wall
10/29
09:00 am
bmrn
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
Medium
Report
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
10/28
01:13 pm
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
10/28
11:43 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Wells Fargo & Company from $90.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Wells Fargo & Company from $90.00 to $70.00. They now have an "overweight" rating on the stock.
10/28
10:58 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $80.00 price target on by analysts at Truist Financial Corporation.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $80.00 price target on by analysts at Truist Financial Corporation.
10/28
10:13 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Stifel Nicolaus from $91.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Stifel Nicolaus from $91.00 to $73.00. They now have a "buy" rating on the stock.
10/28
10:03 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/28
09:14 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Barclays PLC from $86.00 to $80.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Barclays PLC from $86.00 to $80.00. They now have an "overweight" rating on the stock.
10/28
08:10 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at HC Wainwright from $60.00 to $55.00. They now have a "neutral" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at HC Wainwright from $60.00 to $55.00. They now have a "neutral" rating on the stock.
10/28
08:09 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Morgan Stanley from $104.00 to $98.00. They now have an "overweight" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Morgan Stanley from $104.00 to $98.00. They now have an "overweight" rating on the stock.
10/28
07:02 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
10/27
04:03 pm
bmrn
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
Low
Report
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update